<DOC>
	<DOCNO>NCT01291823</DOCNO>
	<brief_summary>Elderly patient esophageal cancer receive thoracic radiation therapy 54-60Gy 30 fraction , concurrent Gefitinib .</brief_summary>
	<brief_title>Gefitinib Combined With Radiotherapy Elderly Patients With Esophageal Cancer</brief_title>
	<detailed_description>Purpose : evaluate efficacy toxicity concomitant treatment use EGFR-TKI thoracic radiation elderly patient esophageal Cancer . Methods : Patients ( &gt; 70 year old ) esophageal Cancer receive thoracic radiation therapy 54-60 Gy 30 fraction concurrent gefitinib 250mg/day .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologically document diagnosis esophageal Cancer Disease must encompass radiotherapy field.Patients celiac , perigastric , mediastinal supraclavicular adenopathy eligible age:7085 year Written inform consent . Performance status 0 2 Neutrophil count &gt; 1.5 x 10 9th power/L platelet &gt; 100 x 10 9th power/L . Hepatic : total bilirubin less equal 1.5 time upper limit normal ( ULN ) Alanine transaminase ( ALT ) aspartate transaminase ( AST ) less equal 2.5 time ULN ( less equal 5 time ULN case know liver involvement Renal : Serum Creatinine less equal 1.5 time upper limit normal ( ULN ) Evidence tracheoesophageal fistula , invasion trachea major bronchus . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 2 year ( For example , carcinoma situ breast , oral cavity , cervix permissible ) . Prior systemic chemotherapy radiation therapy esophageal cancer</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>gefitinib</keyword>
	<keyword>radiation</keyword>
	<keyword>esophageal cancer</keyword>
</DOC>